LNTH:NSD-Lantheus Holdings Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | NASDAQ Global Market

Last Closing

USD 75.52

Change

+1.34 (+1.81)%

Market Cap

USD 0.33B

Volume

0.91M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lantheus Holdings Inc is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products. These products assist clinicians in the diagnosis of cardiovascular and other diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-29 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
UTHR United Therapeutics Corporatio..

-1.52 (-0.47%)

USD 13.60B
NBIX Neurocrine Biosciences Inc

-0.64 (-0.52%)

USD 11.63B
VTRS Viatris Inc

-0.04 (-0.45%)

USD 9.73B
ALKS Alkermes Plc

+0.36 (+1.19%)

USD 4.74B
ALVO Alvotech

+0.30 (+2.69%)

USD 2.92B
HCM HUTCHMED DRC

+0.03 (+0.22%)

USD 2.57B
BCRX BioCryst Pharmaceuticals Inc

-0.13 (-1.19%)

USD 2.09B
KNSA Kiniksa Pharmaceuticals Ltd

+0.18 (+0.66%)

USD 1.92B
SUPN Supernus Pharmaceuticals Inc

+0.02 (+0.06%)

USD 1.80B
EVO Evotec SE ADR

+0.19 (+5.03%)

USD 1.68B

ETFs Containing LNTH

WELL:PA HAN-GINS Indxx Healthcare.. 3.57 % 0.00 %

+0.02 (+-0.39%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 3.57 % 0.00 %

+0.03 (+-0.39%)

N/A
GRPM Invesco S&P MidCap 400 GA.. 3.01 % 0.00 %

-0.41 (-0.39%)

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 1.39 % 0.00 %

+2.25 (+-0.39%)

N/A
QWST 1.37 % 0.00 %

N/A

N/A
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

+0.32 (+-0.39%)

USD 0.35B
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

-1.18 (-0.39%)

N/A
RFG Invesco S&P MidCap 400® .. 0.00 % 0.35 %

+0.19 (+-0.39%)

N/A
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

+0.26 (+-0.39%)

USD 0.44B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

+0.02 (+-0.39%)

N/A
ETLZ:XETRA L&G Russell 2000 US Small.. 0.00 % 0.00 %

-0.11 (-0.39%)

USD 0.09B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.03 (+-0.39%)

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.03 (-0.39%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.58% 45% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.58% 45% F 34% F
Trailing 12 Months  
Capital Gain -6.21% 67% D+ 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.21% 67% D+ 44% F
Trailing 5 Years  
Capital Gain 450.04% 100% F 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 450.04% 100% F 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 69.29% 85% B 91% A-
Dividend Return 69.29% 85% B 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.01% 55% F 27% F
Risk Adjusted Return 104.97% 100% F 98% N/A
Market Capitalization 0.33B 96% N/A 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.70 57% 39%
Price/Book Ratio 6.42 18% 19%
Price / Cash Flow Ratio 13.05 24% 22%
Price/Free Cash Flow Ratio 12.98 31% 29%
Management Effectiveness  
Return on Equity 32.82% 97% 95%
Return on Invested Capital 22.32% 93% 87%
Return on Assets 15.35% 97% 98%
Debt to Equity Ratio 51.96% 29% 37%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.